444 related articles for article (PubMed ID: 10697038)
1. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
4. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
[TBL] [Abstract][Full Text] [Related]
5. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Perez EA; Buckwalter CA; Reid JP
Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
9. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
10. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Markman M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in germ cell cancer.
Motzer RJ; Chou TC; Schwartz L; Bosl GJ; Bajorin DF; Hutter H
Semin Oncol; 1995 Jun; 22(3 Suppl 6):12-5. PubMed ID: 7597428
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
14. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide in the treatment of ovarian cancer.
Markman M
Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
